Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1/2 1Phase 1 1

Status

Not yet recruiting 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 4OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 28Carcinoma, Non-Small-Cell Lung 27Colorectal Neoplasms 17Esophageal Squamous Cell Carcinoma 14Stomach Neoplasms 13Squamous Cell Carcinoma of Head and Neck 13Esophageal Neoplasms 12Cholangiocarcinoma 10Lung Neoplasms 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Small Cell Lung Carcinoma 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Nasopharyngeal Carcinoma 6Melanoma 5Colonic Neoplasms 5Recurrence 4Pancreatic Neoplasms 4Locally Advanced Rectal Cancer 4Hodgkin Disease 4Neoplasms 3NSCLC 3Lymphoma, Extranodal NK-T-Cell 3Glioblastoma 3Carcinoma, Transitional Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2

Interventions

Fluorouracil 87Leucovorin 78Oxaliplatin 77Irinotecan 76Bevacizumab 50Cetuximab 42Capecitabine 42Panitumumab 17Folfox protocol 16Floxuridine 11Chemotherapy, Adjuvant 11regorafenib 10IFL protocol 10Nivolumab 9Drug Therapy 9trifluridine tipiracil drug combination 8Surgical Procedures, Operative 8Neoadjuvant Therapy 8sargramostim 7pembrolizumab 7XELOX 7Specimen Handling 7Biopsy 7Trastuzumab 6Radiotherapy 6Magnetic Resonance Spectroscopy 6HMPL-013 6tislelizumab 5encorafenib 5Trifluridine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Colonic Neoplasms × tislelizumab × Clear all
NCT06124378 2025-09-24

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

First Affiliated Hospital of Guangxi Medical University

Phase 2 Active not recruiting
60 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06709885 2024-11-29

HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 2 Recruiting
100 enrolled
Gastrointestinal

Colonic Neoplasms

NCT06218888 2024-01-23

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases

Fujian Cancer Hospital

Phase 2 Not yet recruiting
17 enrolled
Gastrointestinal

Colonic Neoplasms

NCT05231850 2022-02-09

A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage â…¡ and Stage â…¢ Colon Cancer and dMMR/MSI.

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
70 enrolled
Gastrointestinal

Colonic Neoplasms

NCT04777162 2021-03-04

Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer

Peking University

Phase 2 Unknown
40 enrolled
Gastrointestinal

Colonic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡